Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Alkermes plc is a global biopharmaceutical company specializing in neuroscience-focused medicines. It develops, manufactures, and commercializes proprietary products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, primarily in the U.S. Alkermes also licenses its proprietary technologies, including extended-release injectable and NanoCrystal platforms, to partners worldwide. Its business model combines product sales, royalties, and manufacturing services, targeting patients with serious neurological and psychiatric conditions.
This description was generated via AI from an annual report. Updated about 1 year ago.